Abstract: The disclosed embodiment relates to a composition and system comprising Artificial Intelligence integrated molecular cytology and radiology for triaging of thyroid nodules. More particularly, the composition comprises of biomarkers WGA, Galectin-3, HBME-1 and MAA. The combination of Galectin-3 and WGA expression in cytology-based assay with USG images illustrated a sensitivity of 84% and 96% specificity in delineating benign and malignant nodules. The combination can differentiate cancer and benign nodules of indeterminate nodules with specificity of 93% and sensitivity of 80% using markers and USG. System uses Artificial Intelligence for triaging of thyroid nodules, including a preprocessed fusion model developed using a fully connected neural network. The preprocessed fusion model achieved an AUC of 0.71, which increased to 0.91 (sensitivity: 84%, specificity: 96%) when combined with post-processing scores. Incorporating clinical parameters of TIRAD Bethesda scores further improved the AUC to 0.

Abstract: The present disclosure relates to a panel of biomarkers for the detection/diagnosis and prognosis of head and neck squamous cell carcinoma (HNSCC). Biomarkers for the detection/diagnosis of carcinoma cells identified by proteomic profiling and, detection/identification of selected proteins that are differentially regulated, in a biological sample from an individual as candidate markers. The biomarkers are useful for non-invasive early detection/prognosis focusing on the protein profiling of saliva at different stages of oral pre-cancer and cancer progression. Furthermore, the present invention deals with novel methods of diagnosing and for providing a prognosis for oral cancer and periodontal disease. In addition, the invention also provides kits that are useful for the practice of the methods of the invention.

Abstract: The present invention describes a method utilizing a set of genes or gene products whose altered expression in cancer tissue, particularly head and neck cancer and other carcinomas, or its adjacent normal tissues predicts (a) probability of recurrence in time after treatment (b) sensitivity or resistance to therapies or (c) probability of metastasis at the time of initial discovery of the tumor. Furthermore, the invention describes methods of determining the molecular signature in tumor tissues, tissues adjacent to the tumor, or in saliva by using DNA microarray techniques, quantitative real-time PCR, immunohistochemistry or other methods that are used for determining gene or gene product expression levels.